GOG 244 - The Lymphedema and Gynecologic cancer (LeG) study: The impact of lower-extremity lymphedema on quality of life, psychological adjustment, physical disability, and function

To assess quality of life (QOL) in patients who developed lower-extremity lymphedema (LLE) after radical gynecologic cancer surgery on prospective clinical trial GOG 244. The prospective, national, cooperative group trial GOG-0244 determined the incidence of LLE and risk factors for LLE development,...

Full description

Saved in:
Bibliographic Details
Published in:Gynecologic oncology 2021-01, Vol.160 (1), p.244-251
Main Authors: Carter, Jeanne, Huang, Helen Q., Armer, Jane, Carlson, Jay W., Lockwood, Suzy, Nolte, Susan, Kauderer, James, Hutson, Alan, Walker, Joan L., Fleury, Aimee C., Bonebrake, Albert, Soper, John T., Mathews, Cara, Zivanovic, Oliver, Richards, William Edward, Tan, Annie, Alberts, David S., Barakat, Richard R., Wenzel, Lari B.
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Cervical cancer
Endometrial cancer
Female
Genital Neoplasms, Female - surgery
GOG 244
Humans
Leg - pathology
Lymphedema
Lymphedema - physiopathology
Lymphedema - psychology
Middle Aged
Postoperative Complications - etiology
Postoperative Complications - physiopathology
Postoperative Complications - psychology
Prospective Studies
Quality of Life
Vulvar cancer
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To assess quality of life (QOL) in patients who developed lower-extremity lymphedema (LLE) after radical gynecologic cancer surgery on prospective clinical trial GOG 244. The prospective, national, cooperative group trial GOG-0244 determined the incidence of LLE and risk factors for LLE development, as well as associated impacts on QOL, in newly diagnosed patients undergoing surgery for endometrial, cervical, or vulvar cancer from 6/4/2012–11/17/2014. Patient-reported outcome (PRO) measures of QOL (by the Functional Assessment of Cancer Therapy [FACT]), body image, sexual and vaginal function, limb function, and cancer distress were recorded at baseline (within 14 days before surgery), and at 6, 12, 18, and 24 months after surgery. Assessments of LLE symptoms and disability were completed at the time of lower limb volume measurement. A linear mixed model was applied to examine the association of PROs/QOL with a Gynecologic Cancer Lymphedema Questionnaire (GCLQ) total score incremental change ≥4 (indicative of increased LLE symptoms) from baseline, a formal diagnosis of LLE (per the GCLQ), and limb volume change (LVC) ≥10%. In 768 evaluable patients, those with a GCLQ score change ≥4 from baseline had significantly worse QOL (p 
ISSN:0090-8258
1095-6859
DOI:10.1016/j.ygyno.2020.10.023